875018-66-9

Upstream product

• 915394-87-5 3-(2,4-dichloro-phenyl)-2-oxo-propionic acid 
• 67-56-1 methanol 
• 1109216-86-5 C₉H₈Cl₂O₃ 
• 312300-34-8 (Z)-2-methyl-4-(2,4-dichlorobenzylidene)-5(4H)-oxazolone 
• 874-42-0 2,4-dichlorobenzaldeyhde 
• 68921-92-6 3-(2,4-dichloro-phenyl)-2-hydroxy-propionic acid 

Relevant academic research and scientific papers

Substituted aryl or heteroarylpiperidine derivatives as melanocortin-4 receptor modulators

The present invention relates to substituted aryl or heteroarylpiperidine derivatives of structure (I) as melanocortin-4 receptor modulators. Depending on the structure and the stereochemistry the compounds of the invention are either selective agonists or selective antagonists of the human melanocortin-4 receptor (MC-4R). The agonists can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, anxiety and depression. Generally all diseases and disorders where the regulation of the MC-4R is involved can be treated with the compounds of the invention.

Deracemisation of aryl substituted α-hydroxy esters using Candida parapsilosis ATCC 7330: Effect of substrate structure and mechanism

Candida parapsilosis ATCC 7330 was found to be an efficient biocatalyst for the deracemisation of aryl α-hydroxy esters (65-85% yield and 90-99% ee). A variety of aryl and aryl substituted α-hydroxy esters were synthesized to reflect steric and electronic effects on biocatalytic deracemisation. The mechanism of this biocatalytic deracemisation was found to be stereoinversion.